A review by the MD Anderson group examined the available data with regard to proton therapy for thoracic malignancies, and presented the unique challenges in translating the dosimetric advantages of proton therapy to clinical benefit for patients with thoracic tumors.

Extensive improvements are needed in all aspects of the treatment process, from simulation, planning algorithms, and volumetric image guidance through to real-time tracking and treatment adaptation.